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We have investigated the ability of bFGF to protect cerebellar neurons from neurotoxicity by excitatory amino acids. We have found that 
preincubation with l-2.5 nM bFGF for l-6 days significantly protected neurons from excitotoxic damage via NMDA receptors as well as ionotropic 
non-NMDA receptors. bFGF neuroprotection appeared not to be dependent upon neuronal differentiation and was not mimicked by other 
neurotrophins including BDNF. NT-3 and NGF. A greater ise in extracellular calcium-dependent cGMP formation, following either depolariza- 
tion or excitatory amino acid receptor activation was observed in bFGF-pretreated neurons. We suggest hat neuroprotection from excitotoxicity 
following bFGF treatment may be associated to the modulation of neurochemical pathways dependent upon extracellular calcium influx. 
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1. INTRODUCTION 
Fibroblast growth factors (FGFs) are polypeptide 
mitogens that induce proliferation in a wide variety of 
cell types [l]. Of the seven family members, the best 
characterized are basic and acidic FGF. In addition to 
their mitogenic effects, FGFs may also promote neu- 
ronal survival and outgrowth in the CNS. High levels 
of basic FGF (bFGF) can be found in the developing 
rat brain [2,3], and both basic and acidic FGF have been 
found to be potent neurotrophic factors for cultured 
neurons from multiple CNS regions [4]. 
bFGF has been shown to support the survival in 
primary culture of spinal cord neurons [5,6], 
mesencephalic dopaminergic and GABAergic neurons 
[7], cerebellar granule cells [8], hypothalamic [9], hip- 
pocampal [lO,l 11, cortical [12,13] and neocortical neu- 
rons [14]. 
Beyond its role in normal brain development, bFGF 
may play an important role in the brain response to 
injury and neurodegenerative events. bFGF mRNA has 
been shown to increase in lesioned rat brain and it may 
*Corresponding author. Fax: (34) (8) 510 3534. 
Abbreviations: AMPA, a-amino-3-hydroxy-5-methyl-4-methyl-o-as- 
partate; ANP, atria1 natriuretic peptide; APV, o-(-)-2-amino-5 
phosphovaleric acid; BDNF, brain derived neurotrophic factor; 
bFGF, basic fibroblast growth factor; cGMP, cyclic GMP; CNQX, 
6-cyano-7-nitroquinoxaline-2,3-dione; DIC, days in culture; Dom, do- 
moic acid; Glu, glutamic acid; NGF, nerve growth factor; NT-3, 
neurotrophin-3; NMDA, N-methyl-o-aspartic acid; MK-801, (+)- 
10,1 l-dihydro-5-methyl-5Hdibenzo-[a,d]-cyclohepten-5,1O-imine hy- 
drogen maleate; SNP, sodium nitroprusside; VET, veratrine; VSCC, 
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prevent the degeneration of cholinergic neurons in ani- 
mal models of neurodegenerative disorders [l&16]. On 
the other hand, bFGF has been demonstrated to protect 
cultured rat hippocampal neurons against excitotoxicity 
by glutamic acid [l 11, suggesting a protective role of this 
growth factor in regions particularly vulnerable to both 
acute (e.g. stroke) and chronic (e.g. Alzheimer’s disease) 
neurodegenerative insults. 
Glutamic acid may activate three main receptor 
categories: ionotropic NMDA (activated also by N- 
methyl-o-aspartic acid), ionotropic non-NMDA and 
metabotropic receptors [17]. Recently, bFGF has been 
suggested to protect striatal neurons from glutamic acid 
toxicity by attenuating NMDA receptor function, but 
not from kainic acid toxicity via the ionotropic non- 
NMDA receptor [18]. Here, we have evaluated the neu- 
roprotective effects of bFGF on cerebellar granule cells 
in primary culture. We have found that bFGF strongly 
protects cultured cerebellar neurons from NMDA re- 
ceptor-mediated glutamic acid toxicity as well as from 
neurotoxicity by domoic acid, a tricarboxylic amino 
acid structurally related to kainic acid, acting as a po- 
tent agonist at the ionotropic non-NMDA receptor [ 191. 
2. EXPERIMENTAL 
2.1. Cell cultures 
Primary culture of rat cerebellar neurons were prepared as previ- 
ously described [19]. Briefly, cerebella from 8-day-old pups were dis- 
sected, cells were dissociated and suspended in basal Eagle’s medium 
with 25 mM KCl, 2 mM glutamine, 100 puglml gentamycin and 10% 
fetal calf serum. Cells were seeded in poly-L-lysine coated (5 ,ug/ml) 35 
mm dishes at 2.5 x lo5 cells/cm* and incubated at 37°C in a 5% CO,, 
95% humidity, atmosphere. Cytosine arabinoside (10 PM) was added 
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after 20-24 h of culture to inhibit the replication of non-neuronal cells. 
After 8 days in vitro, morphologically identified granule cells ac- 
counted for more than 95% of the neuronal population, the remaining 
5% being essentially GABAergic neurons. Astrocytes did not exceed 
3% of the overall number of cells in culture. Cerebellar neurons were 
kept alive for more than 40 days in culture by replenishing the growth 
medium with glucose every 4 days and compensating for lost amounts 
of water, due to evaporation [19]. 
2.2. Neurotoxicology 
Primary cultures of cerebellar granule cells were used for toxicolog- 
ical studies at the indicated days in culture. Drugs were added in the 
growth medium. After exposure to the drugs for the indicated time, 
the growth medium was removed and cultures were incubated for 5 
min with 1 ml of incubation buffer containing (in mM): 154 NaCl, 5.6 
glucose, 5.6 KCl, 8.6 HEPES, 1 MgCl,, 2.3 CaCl,, pH 7.4, to which 
the vital stain fluorescein diacetate (5 mg/ml) was added [19]. The 
staining mixture was then aspirated, replaced with incubation buffer, 
and cultures were examined for neurotoxicity. Under 480 nm light, live 
neurons showed a bright green colour in the cell body and the neurites, 
while dead neurons did not retain any fluorescein and their bare nuclei 
could be stained in red by 1 min exposure to 50 mg/ml ethidium 
bromide. Photographs of randomly selected culture fields were taken, 
live and dead neurons were counted, and neuronal survival percentage 
was calculated. Total number of neurons per dish could be calculated 
considering the ratio between the area of the dish and the area of the 
picture (- 2000). In control cultures, live neurons = 1,364,OOO f 
240,000 (mean + S.D., n = 50). 
2.3. Biochemistry 
Intracellular cGMP concentration was determined as previously 
reported [20]. Briefly, cultures were washed twice with 1 ml of pre- 
warmed (37’C) incubation buffer containing (in mM): 154 NaCl, 5.6 
KCl, 5.6 glucose, 8.6 HEPES, 1 MgCl,, 2.3 CaCI,, pH 7.4 (MgCl, was 
omitted when indicated). Dishes (control or pretreated with bFGF as 
indicated) were incubated at 37°C for 10 min with 1 ml of fresh 
incubation buffer and for an additional 20 min with a second 1 ml of 
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fresh incubation buffer. Drugs were added at the end of the 20 min 
incubation period for 1 min (unless otherwise indicated). Antagonists 
were added 1 min before agonists. Incubation was stopped by aspira- 
tion of the solution and addition of 1 ml HCIO, (0.4 N). After neutral- 
izing the perchlorate extract, cGMP content was determined by ra- 
dioimmunoassay. Protein content was determined on the membrane 
pellet from the same sample. 
2.4. Data presentation and analysis 
Results are presented as indicated in each figure. For statistical 
analysis the one-way (Figs. 1,3,4) or the two-way analysis of variance 
(ANOVA) (Fig. 5) was used to identify overall treatment effects, 
followed by the unpaired two-tailed Student’s t-test for selective com- 
parison of individual data groups. Data in Fig. 6 was analyzed by the 
unpaired two-tailed Student’s t-test. Percentage data was transformed 
to arcsin data. Only significances relevant for the discussion of the 
data are indicated in each figure. 
2.5. Materials 
Basic FGF was from UBI; Nifedipine, verapamil and (+)-lo,1 l- 
dihydro-5-methyl-5H-dibenzo-[a,d]-cyclohepten-5,lO-imine hydrogen 
maleate (MK-801) were a generous gift from Dr. G.J. Kaczarowski 
(Merck Sharp and Dohme Laboratories, NJ, USA); CNQX was from 
Tocris Neuramin; Nerve Growth Factor and Atria1 Natriuretic Pep- 
tide were from Peninsula Laboratories Inc.; Domoic acid was from 
Diagnostic Chemicals Ltd., West Royalty Industrial Park, Char- 
lottetown, Canada. All other drugs were from Sigma. 
3. RESULTS 
Excitatory amino acids (EAAs) are potent neurotox- 
ins for cultured cerebellar neurons [19]. In order to 
activate all EAA receptors we used glutamic acid (Glu), 
which was directly added to the culture growth medium. 
One-time addition of 1 nM bFGF to cerebellar neu- 
B 
Fig. 1. Neuroprotective ffect of bFGF against glutamic acid toxicity in cultured cerebellar neurons. (A) Neuronal survival after 24 h exposure 
to 20 PM glutamic acid (GLU) was determined in untreated neurons and in neurons pretreated for 6 DIC (from 5 to 1 IDIC) with 10 pM or 
1 nM bFGF. Represented values are the mean f S.D. of data from 5 independent experiments (n = 5). *P < 0.001 vs. Glu. (B) Cultured neurons 
were simultaneously exposed to fluorescein diacetate (5 min) and to ethidium bromide (1 min). Under 480 nm light, live neurons showed a bright 
green color in the soma and in the neurites (big arrow), and bare nuclei of dead neurons were stained in red (small arrow). Upper panel: control 
neurons exposed to 20pM glutamic acid for 24 h. Lower panel: neurons pretreated with 1 nM bFGF for 6DIC prior to exposure to 20pM glutamic 
acid for 24 h. 
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Fig. 2. Dose-response CUN~ of neuro~rot~t~ve activity of bFGF 
against excitatory amino acid toxicity. Neurons were preincubated 
with the indicated concentrations of bFGF for 7DIC (from 4 to 1 I 
DIG). Neuronal survival was determined after 24 h exposure to 20pM 
glutamic acid (GLU). Values represent he mean AZ S.D. (n = 3). 
mm at 5 days in culture (5 DIC), resulted in a 2.5-fold 
increase in the number of neurons surviving Glu-in- 
duced neurotoxicity at 11 DIC. Thus, while oniy 
32 rt 3.2% of the neurons survived after 24 h exposure 
to 20 FM Glu, neuronal survival in the presence of 1 nM 
bFGF was 65 + 3% (Fig. 1 A). bFGF increased not only 
the number of neurons able to retain fluorescein (Fig. 
IA,B), but also produced a remarkable increase in the 
number of neurites morphologically unaltered after the 
exposure to Glu (Fig. 1B). Lower concentrations of 
bFGF (10 PM) did not show any protective effect 
against Glu neurotoxicity (Fig. 1A). We have not ob- 
served any decrease in the biological activity of bFGF 
with time in culture previously reported by other au- 
thors [1 l]. 
bFGF protection against Glu toxicity was dependent 
upon the ~on~ntration of the growth factor. 50% pro- 
tection was obtained at 20 pM bFGF and it reached a 
maximum at approximately 1 nM (Fig. 2). No further 
effect could be achieved by adding higher doses of the 
growth factor. 
Since cerebellar neurons have been shown to undergo 
differentiation with time in culture [21,22], we next 
asked whether bFGF protection against Glu toxicity 
could be a differentiation-dependent phenomenon_ 
When bFGF (2.5 nM) was added to more differentiated 
cultured cerebellar neurons (9 DIG), it was still effective 
in protecting neurons against Glu neurotoxicity. As 
shown in Fig. 3, among neurons preincubated with 2.5 
nM bFGF for 6 days (from 9 to 15 DIC), 72 + 3% 
survived to 24 h exposure to 20 ,uM Glu (added to the 
cultures at 15 DIC), while only 34 -t 3% of the neurons 
survived in the absence of bFGF. Similar results were 
obtained when bFGF was added to neurons at 11 DIC 
and at 17 DIC, respectively (data not shown). 
Glu neurotoxicity was completely blocked by the 
NMDA receptor antagonists APV (1mM) and MK-801 
(1 @I) ([I91 and data not shown). In order to determine 
whether the protective action of bFGF was specific for 
NMDA-type BAA receptors, we explored the possibil- 
ity that bFGF could be also effective in protecting neu- 
rons against neurotoxicity by domoic acid (DOM), a 
potent agonist at the ionotropic non-‘NMDA receptor 
[19]. AMPA (100 PM), an agonist at the ionotropic 
non-NMDA receptor, quisqualic acid (100 ,uM), an ag- 
onist at both ionotropic non-NMDA and metabotropic 
receptors, and the selective agonist at the metabotropic 
receptor t-ACPD (1 mM), did not produce any neuro- 
toxicity in these cultures (data not shown). Neurotoxio 
ity by DOM could not be prevented by the NMDA- 
receptor antagonists APV (1 mM) and MK-801 (1 PM) 
([19] and data not shown), but it was fully abolished in 
the presence of the ionotropic non-NMDA receptor an- 
tagonist CNQX (20pM) (37 + 4% vs. 82 t 5% neuronal 
survival). As it can be seen in Fig. 4, one time addition 
of bFGF at 5 DIC (Fig. 4A) or at 9 DIC (Fig. 4B) 
protected neurons from neurotoxicity by 24 h exposure 
to DOM (lO,uM), added to the cultures at 11 or 15 DIC, 
respectively. Thus, 71 + 2% and 75 f 5% of the neurons 
that received bFGF at 5 DIC or at 9 DIC respectively 
survived after the exposure to DOM, while only 
37 +- 4% and 40 + 2% of the neurons survived to DUM 
in the absence of the growth factor. 
5 DIC 9 DIC 
Fig. 3. bFGF protection from glutamic acid neurotaxicity is independ- 
ent of neurnnai age in culture. bFGF was added to cuhured neurons 
at 5DIC or 9 DIG. Neuronal survival was determined after 24 h to 20 
pM ghttamic acid (GLU) exposure, added to the neurons at 1 I DK 
and IS DIG respectively. Values represent he mean k SD. (n = 4) 
*P < 0.001 M. GLLJ. 
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Fig, 4. ~europr~t~ive effect of bFGF against domoic acid toxicity 
in cultured cerebellar neurons. Neuronal survival after 24 h exposuiz 
to 10 PM domoic acid (DOW was determined in untreated neurons 
and in neurans pretreated for 6 days with bFGF. bFGF was added 
at 5 DIC (A) or at 9 DIC (B). Values represent he mean zk S.D. 
(n = 3-5). *P < 0.001 vs. DOM. 
We also tested the time dependence of exposure to 
bFGF on protection against Glu or DOM neurotoxic- 
ity. bFGF was added to the cultures 2, 5 or 24 h prior 
to exposure to either 20 ,uM Glu or 10 ,ttm DOM. Cell 
survival 24 h following exposure to the toxins was par- 
tially but signikantly enhanced in cultures pretreated 
with bFGF for 24 h but not in cultures pretreated with 
the growth factor for 2 or 5 h (data not shown). These 
findings indicate that the ability of bFGF to protect 
from EAA neurotoxicity required a relatively long-term 
exposure, 
The protective effect of bFGF was specific in that 
preincubation of the neurons for 12 DIC (from 3 to 15 
DIC) with BDNF (12 nglml) or NT3 (12 rig/m.... added 
to the cultures twice, at 3 DIC and at 10 DIC, not only 
did not result in any protection from either Glu or 
DOM toxicity (Fig. 51, but these neurotrophi~s ign& 
cantly enhanced the toxic e&ct of the EAAs. in partic- 
ular, BDNF increased Glu but not DOM toxicity, while 
NT-3 enhanced DQM toxicity to a higher extent than 
Glu toxicity. Pretreatment of the cultures with NGF 
(l-50 ng/ml) did not increase the number of neurons 
surviving to 20 PM Glu or 10 ,uM DON (Fig. 5). 
We then attempted to elucidate which mechanism 
could be possibly involved in bFGF neuroprotection. It 
has been suggested that bFGF may participate in the 
control of intracellular calcium ~on~ntration [11 f. We 
therefore investigated whether bFGF protection against 
Glu and DOM neurotoxicity might be reflected in 
changes in extracellular calcium influx, by measuring 
the intracellular formation of cGMP stimulated by 
EAA, which depends upon extracellular calcium influx 
and nitric oxide synthase [20,23]. cGMP formation fol- 
lowing exposure to 100 ,uM Glu in the absence of Mg2+ 
was significantly increased (165%) in cultures pretreated 
with bFGF (2.5 nM) for 6 DIC (Fig. 6A). Pretreatment 
with bFGF did not alter cGMP levels in unstimulated 
cultures, nor affected Mg’+ (1 mM) block of Glu-stimu- 
lated cGMP formation. MR-801 (1 PM) completely an- 
tagonized GLU stimulation of cGMP both in bFGF 
treated and untreated cultures. Selective NMDA recep- 
tor-mediated stimulation of cGMP formation by 
NMDA (100 ,uM) was unaffected by bFGF pretreat- 
ment (Fig. 6A), while non-NMDA stimulation of 
cGMP formation by DOM was significantly increased 
in culture: ; 3 1 
100 
bretreated with bFGk (163%; Fig. 6B). 
COMROL 
BDW 
NT-? 
NGF 
Fig. 5. Brain-derived neurotrophic factor, neurotrophin-3 and nerve 
growth factor do not protect cultured cerebellar neurons from excita- 
tory amino acid toxicity. Neurotrophins were added to the cultures 
twice, at 3 and 10 DIG, and excitatory amino acids were added at 12 
DIC. Neuronal survival was determined after 24 h exposure to glu- 
tank acid (GLU) or domoic acid (DOM). Concentrations were, 
BDNF and NT-3, 12 ng/ml; NGF, l-50 r&ml; GLU, 20 pM; DOM, 
10 PM. Values represent he mean f S.D. (n = 3-4). *P <: 0.005 and 
*P < 0.03 vs. CONTROL within the same treatment. “P 4 0.02 vs. 
same trophin in GLU. 
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Fig. 6. bFGF increases excitatory amino acid and depolarization-induced stimulation of cGMP formation. Cerebellar cultures were either untreated 
(NONE) or exposed to bFGF (2.5 nM) for 6 DIC (from 5 to 11 DIC). At 11 DIC, neurons were exposed for 1 min to the indicated drugs (except 
in panel D). Antagonists were added 1 min before stimulation. cGMP levels in the absence (A) or in the presence (B-D) of I mM Mg’+ in 
unstimulated cultures were defined as CONTROL. Data are reported as the mean 5 S.D. (n = 3). In panel A, stimulation of cGMP was performed 
both in the absence (-Mg) and in the presence (+Mg) of Mg*+. Concentrations were, GLU and NMDA, 100,uM; MK-801 (MK), 1 PM. *P < 0.01 
vs. GLU-Mg in the absence of bFGF. (B) Stimulation of cGMP by DOM (20 ,uM). MK-801 (MK), 1 PM. *P < 0.04 vs. same treatment in the 
absence of bFGF (NONE). (C) Depolarization-induced stimulation of cGMP formation by 30 pug/ml veratrine (VET). Nifedipine (NIF, 10 PM); 
Verapamil (VER; 10pM). *P < 0.003 vs. same treatment in NONE. 'P < 0.001 vs. VET in NONE. In panel D, cGMP formation by atria1 natriuretic 
peptide (ANP, 0.1 PM x 2 min) or sodium nitroprusside (SNP; 1 mM x 2 min). *P < 0.05 vs. SNP in NONE. 
DOM stimulation of cGMP both in the presence or in 
the absence of bFGF was not reduced by MK-801 (Fig. 
6B), and DOM stimulation of cGMP was completely 
antagonized by CNQX (data not shown). In order to 
verify whether bFGF pretreatment could also increase 
cGMP formation following stimulation of VSCC, cere- 
bellar neurons were depolarized using veratrine (VET, 
30 pg/ml). Stimulation of cGMP by VET was signifi- 
cantly antagonized (63%) by the dihydropiridine nifed- 
ipine (NIF; lOpM), and to a higher extent (78%) by the 
phenylalkylamine verapamil (VER; 10 PM). MK-801 (1 
PM) partially antagonized (40%) VET stimulation of 
cGMP formation. Neither NIF nor VER antagonism of 
VET stimulation of cGMP was enhanced in the pres- 
ence of MK-801 (Fig. 6C). VET stimulation of cGMP 
formation was significantly increased (226%) by bFGF 
pretreatment, and this enhancement was not reduced in 
the presence of MK-801 (Fig. 6C). 
bFGF treatment selectively increased the stimulation 
of cGMP formation via EAA receptors and VSCC, 
since cGMP formation by atria1 natriuretic peptide 
(lo-’ M) [20] was not different in bFGF treated vs 
untreated cultures, and cGMP formation by the direct 
guanylate cyclase activator sodium nitroprusside (1O-3 
M) [20] was slightly (20%) although significantly re- 
duced in the presence of bFGF. 
4. DISCUSSION 
In the present study, we have investigated the ability 
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of bFGF to influence cerebellar neurons sensitivity to 
neurotoxicity by EAAs occurring either via the NMDA 
receptor as for Glu, or via the ionotropic non-NMDA 
receptor as for DOM. We have found that only one time 
addition of l-2.5 nM bFGF was required to signifi- 
cantly protect cerebellar neurons from neurotoxicity by 
Glu as well as from toxicity by DOM. Neuroprotection 
was maximal at approximately 1 nM bFGF (- 20 ngl 
ml), and then it leveled off. This concentration is consis- 
tent with previously reported values for peak effective- 
ness of bFGF in supporting the survival of cerebellar 
granule neurons in culture [8] as well as of other culture 
systems [14]. However, it is 4-lo-fold greater than the 
reported value for bFGF maximal effects in hippocam- 
pal neurons [10,11,24] and other cultures [5,12]. 
The biological response of cells to bFGF is mediated 
through specific receptors which have been shown to be 
members of the tyrosine kinase receptor family and to 
be phosphorylated upon binding of bFGF via an inter- 
molecular transphosphorylation mechanism [25,26]. 
bFGF mRNA and FGF receptor mRNA are widely 
expressed in the adult rat central nervous system [27,28]. 
High levels of FGF receptor mRNA have been detected 
in the cerebellar granule cell layer, whereas the Purkinje 
cell and molecular layers were found to express little 
FGF receptor mRNA [28]. Very little or none FGF 
mRNA was detected in total RNA from rat cerebellum 
[27]. These findings suggest that cerebellum granule 
cells are responsive to bFGF synthesized in vivo either 
by glial cells or by other type of neurons. We have 
observed no neuronal protection from Glu or DOM in 
mixed neuronal-astrocyte cultures (data not shown), 
suggesting that bFGF may be synthesized in vivo by 
neuronal or non-neuronal populations not present in 
these cultures. Since FGF mRNA expression increases 
in lesioned rat brain [29], exogenously administered 
bFGF protection could be mimicking an in vivo situa- 
tion where the factor is released following lesion. 
bFGF-mediated protection appeared to be specific, 
since no protection was observed against Glu or DOM 
toxicity in cultures pretreated with BDNF or NT-3. 
Both neurotrophins have been suggested to play an im- 
portant role in the development of the cerebellum 
[30,31] and BDNF mRNA levels were increased upon 
stimulation of Glu receptors in hippocampus and cortex 
[32,33]. Although BDNF and NT-3 may have critical 
functions in the development of the cerebellum as previ- 
ously suggested [30], our results here indicate that in- 
creased levels of these factors do not result in any pro- 
tective effect from excitotoxic damage of cerebellar neu- 
rons in vitro, and therefore do not seem to support a 
general protective role for BDNF or NT-3 during exci- 
totoxic brain damage. 
It has been suggested that some of the neurotrophic 
effects of FGF could be mediated by the enhancement 
of the neurotrophic activities of astrocytes. Thus, FGF 
has been shown to regulate nerve growth factor synthe- 
sis and secretion by astrocytes and fibroblasts [34]. Such 
an effect is unlikely to account for the neuroprotective 
effect of bFGF documented in the present study, since 
non-neuronal cell proliferation in these cultures was 
prevented with mitotic inhibitors, and they constitute 
only about 3% of the cells. Moreover, addition of up to 
50 ng/ml NFG had no effect on the number of neurons 
surviving to neurotoxic concentrations of Glu or DOM, 
and exogenously added BDNF or NT-3 did not increase 
the neuronal survival after exposure to the toxins either. 
Thus, we suggest that bFGF neuroprotection in these 
cultures may be mediated through a direct interaction 
between bFGF and bFGF receptors on the neuronal 
surface, and not through an indirect stimulation and 
release of neurotrophins by non-neuronal cells. Previ- 
ous studies support the view that bFGF acts directly on 
neurons [10,35]. However, we cannot rule out that 
growth factors other than NGF, BDNF or NT-3 could 
be released by the few glia cells present in these cultures 
and played an intermediary role in the neuroprotective 
action of bFGF. 
Our data indicate that the mechanism by which 
bFGF protects neurons from toxicity may involve 
changes in calcium-dependent second messengers. A 
greater rise in cGMP formation, which depends on ex- 
tracellular calcium influx, was observed in bFGF-pre- 
treated neurons after exposure to EAAs or after depo- 
larization of the neurons with veratrine. These observa- 
tions are consistent with the possibility that bFGF 
might modify calcium influx via modulation of VSCC 
number or function, as already suggested for growth 
factors in other cell types [36]. No increase in cGMP 
formation was observed in unstimulated cultures pre- 
treated with bFGF in comparison with untreated cul- 
tures, consistent with previous data showing that FGF 
alone did not significantly alter basal levels of intracel- 
lular calcium in hippocampal neurons [ll]. It is worth 
noting that cGMP formation by NMDA was not en- 
hanced in bFGF pretreated neurons, suggesting a role 
for calcium conductances other than NMDA receptor- 
associated channels in bFGF neuroprotection. Studies 
are currently in progress in order to test this hypothesis. 
Our preliminary results suggest a selective involvement 
of VSCC in bFGF action. 
bFGF has been suggested to reduce Glu toxicity in 
cultured hippocampal neurons by preventing Glu-in- 
duced rises in intracellular calcium [l 11. Our findings 
that cGMP formation was increased in bFGF-treated 
neurons upon stimulation either by Glu or DOM, or 
upon depolarization, suggest that bFGF protection in 
cultured cerebellar granule neurons may involve an ele- 
vation rather than a decrease in intracellular calcium. 
Several ines of evidence support the view that cultured 
hippocampal neurons and cerebellar granule cells may 
follow different regulation patterns. Thus, a depolariza- 
tion-induced calcium influx is essential in securing the 
maintenance of cerebellar granule cells in culture, and 
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a K’ concentration of 25 mM is required in the growth 
medium [37], while hippocampal neurons are usually 
maintained in culture in as low as 5 mM K+. Neuronal 
sensitivity to excitotoxicity is also different in both types 
of cultures, so that only 20 PM Glu is needed to produce 
60% reduction in cerebellar neuron survival [IQ com- 
pared with 200 PM Glu for hippocampal neurons [I I]. 
As mentioned above, cerebellar granule cells are 
maintained in culture under depolarizing conditions (25 
mM KC]), allowing a throphic influx of calcium inside 
the cell [37]. It has been recently shown that rises in 
intracellular calcium may lead to inactivation of 
NMDA channels, and inactivation could be triggered 
by opening of either NMDA or VSCC [38]. However, 
neither ligand binding nor channel opening was abso- 
lutely required to elicit this calcium-dependent inactiva- 
tion [38]. It could be conceivable that by enhancing an 
existing calcium current resulting from spontaneous ac- 
tivity, bFGF lowered the number or function of 
NMDA-receptors available on the neuronal surface. 
NMDA channel inactivation was suggested to occur by 
calcium binding to either the channel itself or a nearby 
regulatory protein to alter channel gating [38]. Since 
bFGF protection from EAA toxicity in granule cells 
required rather long exposure times, it would be con- 
ceivable to suggest an action on a calcium-dependent 
regulatory protein. This sort of mechanism could ex- 
plain bFGF protection from Glu toxicity involving the 
NMDA receptor. However, since neurotoxicity by 
DOM was not prevented by the NMDA-channel 
blocker MK-801, other mechanisms for bFGF protec- 
tion from DOM toxicity must be involved. bFGF has 
been shown to affect gene expression in a variety of cell 
types, including neurons [39,40], and the protective ef- 
fects of bFGF against EAA toxicity may be also medi- 
ated by actions on protein expression. The observations 
that bFGF protection required pretreatment prior to 
the insult would be consistent with this possibility. Ex- 
periments are currently carried out in order to clarify 
this mechanism. 
In conclusion, we have shown here that long expo- 
sures of cultured cerebellar granule cells to bFGF, pro- 
tected neurons against excitotoxicity by Glu via the 
NMDA receptor and by DOM, specifically acting at the 
non-NMDA receptor. Our data indicate that bFGF 
may be regulating intracellular second messenger levels 
depending on calcium influx, thus suggesting that cal- 
cium influx may play a key role in different signalling 
pathways associated to neuronal degeneration and neu- 
ronal death. 
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